Sumitomo Pharma Co.ltd. · TSE:4506

Sumitomo Pharma Co.ltd — Q2 FY2026 Earnings Presentation

28 slides from Sumitomo Pharma Co.ltd's earnings presentation, Oct 30, 2026

  1. Slide 1: Conference on Q2 FY2026 Financial Results

    Conference on Q2 FY2026 (April 1, 2026 to September 30, 2026) Financial Results Toru Kimura, President and CEO Sumitomo Pharma Co., Ltd. October 30, 2026

  2. Slide 2: Disclaimer Regarding Forward-looking Statements

    Disclaimer Regarding Forward-looking Statements This material contains forecasts, projections, goals, plans, and other forward-looking statements regarding the Group’s financial results and other data. Such forward-looking statements are based on the Company’s assumptions, estimates, outlook, and ot

  3. Slide 3: Financial Results for Q2 FY2026

    Financial Results for Q2 FY2026 © Sumitomo Pharma Co., Ltd. All Rights Reserved. 2

  4. Slide 4: Financial Results for Q2 FY2026 (Core Basis)

    Financial Results for Q2 FY2026 The forecasts for FY2026 were revised Financial Results for Q2 FY2026 (Core Basis) (See P.8) Billions of JPY Q2YTD Q2YTD Change FY2026 Year-on-year FY2025 FY2026 July 31 1H Progress  Revenue Results Results Value FX Impact % Forecasts % Revenue increased primarily du

  5. Slide 5: Revenue of Major Products in the U.S.

    Financial Results for Q2 FY2026 Revenue of Major Products in the U.S. Change FY2026 Average rates: Q2YTD Q2YTD Q2YTD Q2YTD Q2 FY2025 Results : 1US$ = ¥146.03 FY2025 FY2026 Change FY2025 FY2026 JPY-basis Q2 FY2026 Results : 1US$ = ¥159.49 FX Results Results Results Results Value % May 13 Forecasts Im

  6. Slide 6: Revenue of Major Products in Japan

    Financial Results for Q2 FY2026 Revenue of Major Products in Japan Billions of JPY Q2YTD Q2YTD Change FY2026 FY2025 FY2026 May 13 Progress Results Results Value ％ Forecasts % Japan XEPLION®/XEPLION TRI® － 8.2 8.2 － 17.1 48.0  Commencement of sales of XEPLION ®/XEPLION TRI ® LATUDA® 6.9 7.3 0.4 5.2

  7. Slide 7: Gross Profit by Region (Core Basis)

    Financial Results for Q2 FY2026 Gross Profit by Region (Core Basis) Billions of JPY Japan U.S. Other Total Japan Q2YTD Revenue 44.6 197.8 24.1 266.5  Gross profit decreased due to the change in FY2026 Cost of sales 25.0 78.1 20.4 123.5 product mix Results Gross profit 19.6 119.7 3.6 143.0 U.S.  Gr

  8. Slide 8: Financial Forecasts for FY2026

    Financial Forecasts for FY2026 © Sumitomo Pharma Co., Ltd. All Rights Reserved. 7

  9. Slide 9: Financial Forecasts for FY2026 (Core Basis)

    Financial Forecasts for FY2026 Financial Forecasts for FY2026 (Core Basis) Billions of JPY FY2026 FY2026 Change from Previous Forecasts May 13 Revised FX rates: Forecasts Forecasts Value FX Impact % FY2026 Revenue 540.0 565.0 25.0 6.1 4.6 Previous Forecasts : 1US$ = ¥155.00 Revised Forecasts : 1US$

  10. Slide 10: Revenue of Major Products in the U.S.

    Financial Forecasts for FY2026 Revenue of Major Products in the U.S. FY2026 FY2026 FY2026 FY2026 Change FX rates: May 13 Revised Change May 13 Revised FY2026 Forecasts Forecasts Forecasts Forecasts Value FX Impact % Previous Forecasts : 1US$ = ¥155.00 Revised Forecasts : 1US$ = ¥157.00 U.S. Millions

  11. Slide 11: ORGOVYX

    Financial Forecasts for FY2026 ORGOVYX®  Q2 YTD: Performed as planned and achieved 102% of net sales versus original forecast Annual sales forecast revised upward to $1,359M (+$5M) Plan for Q2 Actual for Q2 Year-over-year Variance Analysis YTD FY2026 YTD FY2026 comparison Between Original and Revis

  12. Slide 12: GEMTESA

    Financial Forecasts for FY2026 GEMTESA®  Q2 YTD: Achieved 117% of net sales versus original forecast primarily driven by temporary pricing impacts Annual sales forecast revised upward to $752M (+$66M) Plan for Q2 Actual for Q2 Year-over-year Variance Analysis YTD FY2026 YTD FY2026 comparison Betwee

  13. Slide 13: Gross Profit by Region (Core Basis)

    Financial Forecasts for FY2026 Gross Profit by Region (Core Basis) Billions of JPY Japan U.S. Other Total Japan FY2026 Revenue 88.5 425.1 51.4 565.0  Higher gross profit driven by upward revisions to Revised Cost of sales 50.7 152.3 43.0 246.0 TWYMEEG® sales forecast, with a limited Forecasts Gross

  14. Slide 14: Research and Development

    Research and Development © Sumitomo Pharma Co., Ltd. All Rights Reserved. 13

  15. Slide 15: Development Pipeline (As of October 30, 2026)

    Research and Development Development Pipeline (As of October 30, 2026) Revisions since the announcement in July 2026 are shown in red Area Generic Name/Product Code Mechanism of Action, etc. Planned Indication(s) Development Stage Serotonin 5-HT2A receptor antagonist and serotonin 5-HT1A DSP-0038 Al

  16. Slide 16: Major Topics in Clinical Development (August 1 – October 30, 2026)

    Research and Development Major Topics in Clinical Development (August 1 – October 30, 2026)  Psychiatry & Neurology  AMCHEPRY® / raguneprocel / CT1-DAP001 / DSP-1083 Parkinsonʼs disease Japan: ・First patient transplantation completed in the post-marketing clinical study (Phase 4 study) of allogene

  17. Slide 17: AMCHEPRY Post-Marketing Clinical Study (Phase 4 Study) Schedule

    Research and Development AMCHEPRY® Post-Marketing Clinical Study (Phase 4 Study) Schedule  Advancing site activation and patient enrollment readiness for the Phase 4 study  The first patient transplantation was completed at Kyoto University Hospital in October 2026  Approximately 1–2 patients are

  18. Slide 18: Allogeneic iPS Cell-Derived Retinal Sheet (DSP-3077) for Retinitis Pigmentosa

    Research and Development Psychiatry & Neurology: Allogeneic iPS Cell-Derived Retinal Sheet (DSP-3077) for Retinitis Pigmentosa  Retinal sheet transplantation was performed in multiple patients in the U.S. Phase 1/2 study  The Q2 FY2026 milestone was achieved, and the clinical study is progressing

  19. Slide 19: fH1/DSP-0546LP Universal Influenza Vaccine

    Research and Development Others: fH1/DSP-0546LP Universal Influenza Vaccine  Favorable safety and tolerability were observed through one year after administration, and anti-LAH antibody titers remained elevated DSP-0546LP Adjuvant  A controlled human infection study is planned to begin by the end

  20. Slide 20: Key Development Products: Major Milestones Scheduled in FY2026

    Revisions since the announcement in July 2026 are shown in red Research and Development Key Development Products: Major Milestones Scheduled in FY2026 (as of October 30, 2026) Area Program Q1 Q2 Q3 Q4 Remarks DSP-0378 Initial PoC* (Progressive Myoclonic Epilepsy Developmental Epileptic Encephalopath

  21. Slide 21: Appendix Contents

    Appendix ＜Contents＞ P.21 Financial Results for Q2 FY2026 Financial Results for Q2 FY2026 (Full Basis) P.22 Financial Results for Q2 FY2026 Financial Position and Cash Flow P.23 Financial Results for Q2 FY2026 Prescription Trends of GEMTESA® P.24 Financial Forecasts for FY2026 Revenue of Major Produc

  22. Slide 22: Financial Results for Q2 FY2026 (Full Basis)

    Appendix (Financial Results for Q2 FY2026) Financial Results for Q2 FY2026 (Full Basis) Billions of JPY Q2YTD Q2YTD Change FY2025 FY2026 Results Results Value ％ Revenue 227.1 266.5 39.4 17.3 Cost of sales 89.7 123.5 33.8 37.7 Gross profit 137.4 143.0 5.5 4.0 SG&A expenses 76.6 78.7 2.2 2.8 R&D expen

  23. Slide 23: Financial Position and Cash Flow

    Appendix (Financial Results for Q2 FY2026) Financial Position and Cash Flow Billions of JPY As of March As of Sep. Ｂ/Ｓ Change 2026 2026 Assets 804.6 851.1 46.5 Goodwill / Intangible assets 371.6 361.7 (9.9) Trade and other receivables 131.4 152.0 20.6 Cash and deposit / Short-term loan receivable 44

  24. Slide 24: Prescription Trends of GEMTESA

    Appendix (Financial Results for Q2 FY2026) Prescription Trends of GEMTESA®  GEMTESA® prescriptions, including total and new prescriptions, continued to increase despite the launch of Mirabegron generics in Apr. 2024 K K 900 TRx in β-3 Market 120 NBRx in β-3 Market ジェムテサ その他 β3受容体作動薬 ジェムテサ その他 β3受容体

  25. Slide 25: Revenue of Major Products in Japan

    Appendix (Financial Forecasts for FY2026) Revenue of Major Products in Japan Billions of JPY FY2026 FY2026 Change May 13 Revised Value ％ Forecasts Forecasts Japan XEPLION®/XEPLION TRI® 17.1 17.1 － － LATUDA ® 13.6 13.9 0.3 2.2 TWYMEEG® 11.9 13.2 1.3 10.9  TWYMEEG® sales forecast revised upward to re

  26. Slide 26: Product Launch Target (as of October 30, 2026)

    Revisions since the announcement in July 2026 are shown in red Appendix (Research and Development) Product Launch Target (as of October 30, 2026) Psychiatry & Oncology Neurology FY2026 2027 2028 2029 2030 CT1-DAP001/DSP-1083 (Allogeneic iPS cell-derived Parkinson’s disease Development dopaminergic n

  27. Slide 27: Regenerative Medicine/Cell Therapy Launched Product and Development Pipeline (RACTHERA)

    Appendix (Research and Development) Revisions since the announcement in July 2026 are shown in red Regenerative Medicine/Cell Therapy Launched Product and Development Pipeline (RACTHERA Co., Ltd.) (as of October 30, 2026) Brand name/Cell type JP/ Clinical Approval Approval→ Indications Pre-clinical

  28. Slide 28: Sumitomo Pharma

    <> Sumitomo Pharma Innovation today, healthier tomorrows

Sumitomo Pharma — Q2 FY2026 Earnings Presentation on 6ix